Phio Net Income from 2010 to 2026
| PHIO Stock | USD 1.03 0.11 9.65% |
Net Loss | First Reported 2011-03-31 | Previous Quarter -2.2 M | Current Value -2.4 M | Quarterly Volatility 1.8 M |
Check Phio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Phio Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 K, Interest Expense of 278.9 K or Other Operating Expenses of 8.8 M, as well as many indicators such as Price To Sales Ratio of 275, Dividend Yield of 0.0092 or PTB Ratio of 0.33. Phio financial statements analysis is a perfect complement when working with Phio Pharmaceuticals Valuation or Volatility modules.
Phio | Net Income | Build AI portfolio with Phio Stock |
Evaluating Phio Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Phio Pharmaceuticals Corp's fundamental strength.
Latest Phio Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Phio Pharmaceuticals Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Phio Pharmaceuticals Corp financial statement analysis. It represents the amount of money remaining after all of Phio Pharmaceuticals Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Phio Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Phio Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.15 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Phio Net Income Regression Statistics
| Arithmetic Mean | (10,532,713) | |
| Coefficient Of Variation | (30.68) | |
| Mean Deviation | 2,165,144 | |
| Median | (10,219,000) | |
| Standard Deviation | 3,231,237 | |
| Sample Variance | 10.4T | |
| Range | 13.8M | |
| R-Value | 0.37 | |
| Mean Square Error | 9.6T | |
| R-Squared | 0.14 | |
| Significance | 0.14 | |
| Slope | 236,661 | |
| Total Sum of Squares | 167.1T |
Phio Net Income History
Other Fundumenentals of Phio Pharmaceuticals Corp
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Phio Pharmaceuticals Net Income component correlations
About Phio Pharmaceuticals Financial Statements
Phio Pharmaceuticals investors utilize fundamental indicators, such as Net Income, to predict how Phio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.2 M | -8.6 M | |
| Net Loss | -8.2 M | -8.6 M | |
| Net Loss | -15.3 M | -16 M | |
| Net Loss | (8.17) | (8.58) | |
| Net Income Per E B T | 0.80 | 0.70 |
Pair Trading with Phio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Phio Stock
| 0.39 | VERA | Vera Therapeutics | PairCorr |
| 0.35 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.34 | DSGN | Design Therapeutics | PairCorr |
| 0.32 | EQ | Equillium | PairCorr |
| 0.32 | DRTS | Alpha Tau Medical | PairCorr |
The ability to find closely correlated positions to Phio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phio Pharmaceuticals Corp to buy it.
The correlation of Phio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phio Pharmaceuticals Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Phio Pharmaceuticals Correlation against competitors. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Biotechnology sector continue expanding? Could Phio diversify its offerings? Factors like these will boost the valuation of Phio Pharmaceuticals. Anticipated expansion of Phio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Phio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Phio Pharmaceuticals Corp's market price often diverges from its book value, the accounting figure shown on Phio's balance sheet. Smart investors calculate Phio Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Phio Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Phio Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Phio Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.